WILKES-BARRE, Pa. and SUNNYVALE, Calif., May 3, 2021 /PRNewswire/ -- Geisinger continues to bring advanced cancer care closer to home as it is the first hospital system in the U.S. to offer Accuray Incorporated's (NASDAQ: ARAY) newest Synchrony® technology on both the CyberKnife® S7™ and Radixact® Systems to better aim radiation beams and minimize damage to non-cancerous tissue during treatment.
As part of Geisinger's expansion project at its Frank M. and Dorothea Henry Cancer Center, the health system recently began providing care using the one-of-a-kind Synchrony Motion Synchronization and Real-Time Adaptive Radiotherapy Technology on its CyberKnife S7 and Radixact Systems.
Synchrony uses artificial intelligence to adapt radiation treatment delivery in real-time to tumor movement during the treatment session, with the goal of delivering a more targeted radiation dose to the tumor, in less time, to improve outcomes. Synchrony is designed to correct the radiation beam if a tumor moves because of bodily processes such as breathing or digestion, as well as patient movement that may occur during treatment.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
"We continue to invest in state-of-the-art technology, like Synchrony and CyberKnife, to provide the most advanced treatment options for our neighbors fighting cancer," said Dr. Anand Mahadevan, chairman of radiation oncology at Geisinger. "Along with our continued investment in the Henry Cancer Center, this is yet another way we're making better health easier for our patients and bringing these life-saving tools to the communities where they live right here in northeastern Pennsylvania."
Geisinger's team at the Henry Cancer Center at Geisinger Wyoming Valley Medical Center began treating patients using the CyberKnife® S7™ System in March 2020, the only such system in northeastern Pennsylvania. This latest advancement and upgrade with the Synchrony® technology allows Geisinger to offer hypofractionated radiotherapy – a shorter course of radiotherapy with higher radiation doses per fraction – without sacrificing the precision and accuracy required for high dose treatments.
"We congratulate the Geisinger team on their treatment milestone and look forward to continuing to partner with them to enhance cancer patient care," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "Accuray has been a pioneer in the development of high precision radiation therapy technology that supports the growing use of ultra-hypofractionated treatments. Synchrony technology was developed on the CyberKnife System more than 15 years ago, and based on overwhelming customer feedback and clinical evidence we applied this unique capability to the Radixact® System. While the two systems deliver radiation in different ways, they both are able to leverage the Synchrony real-time delivery adaptation to provide more precise, accurate treatments while maximizing patient comfort. We're inspired by how Geisinger is leading with this technology and positively changing the lives of patients and their families."